Michael C. Milone
Co-Founder & Co-Chair of Scientific Advisory BoardDr. Michael C. Milone, M.D., Ph.D., is Co-Founder of Cabaletta Bio, Inc. and serves as its Co-Chair of Scientific Advisory Board. He has been Co-Founder and Co-Chair of Scientific Advisory Board at Verismo Therapeutics, Inc. Dr. Milone is an Associate Professor of Pathology and Laboratory Medicine and founding member of the Center for Cellular Immunotherapies at the University of Pennsylvania. He has experience in immunology and in the development of genetically-engineered T cell therapies including a post-doctoral fellowship with Carl June, M.D. from 2004 – 2007. He is a co-inventor of CTL019 (tisagenlecleucel), the first chimeric antigen receptor (CAR)-based T cell therapy to reach regulatory approval in the US and Europe, as well as several new CAR-T cell therapies for multiple myeloma and solid tumors that are currently in early phase clinical trials. Dr. Milone leads a team of translational researchers in the development of novel genetically engineered T cells for adoptive T cell immunotherapy. Dr. Milone is a graduate of the accelerated B.S-M.D. program between Stevens Institute of Technology and New Jersey Medical School. He holds a B.S. in Chemical Biology from the Stevens and received his M.D. and Ph.D. degree in experimental pathology in 1999 from the University of Medicine and Dentistry of New Jersey (now part of Rutgers). He is a board-certified pathologist, completing an internship in Internal Medicine, residency in Clinical Pathology and fellowship training in Transfusion Medicine at the Hospital of the University of Pennsylvania. He continues to maintain a clinical practice as the Associate Director of the Toxicology Laboratory at the Hospital of the University of Pennsylvania and has received several awards for his excellence in teaching and research.
Positions
- Company NameCabaletta Bio, Inc.Stock CodeCABAPositionCo-Founder & Co-Chair of Scientific Advisory BoardColleagues
